Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase

Wei Chen [†], Guoqiang Dong [†], Shipeng He [†], Tianying Xu, Xia Wang, Na Liu, Wannian Zhang, Chaoyu Miao [*], Chunquan Sheng [*]

School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People's Republic of China

ABSTRACT

Nicotinamide phosphoribosyltransferase (Nampt) is an attractive therapeutic target for cancer. A Nampt inhibitor with novel benzothiophene scaffold was discovered by high throughput screening. Herein the structure–activity relationship of the benzothiophene Nampt inhibitor was investigated. Several new inhibitors demonstrated potent activity in both biochemical and cell-based assays. In particular, compound **16b** showed good Nampt inhibitory activity ($IC_{50} = 0.17 \,\mu M$) and in vitro antitumor activity ($IC_{50} = 3.9 \,\mu M$, HepG2 cancer cell line). Further investigation indicated that compound **16b** could efficiently induce cancer cell apoptosis. Our findings provided a good starting point for the discovery of novel antitumor agents.

© 2015 Published by Elsevier Ltd.

Cancer is a disease of genetic heterogeneity, but the metabolic alternation is the common future of malignant cells.[1,2] Although Warburg suggested that energy generation in cancer cells switch form the Krebs (tricarboxylic acid) cycle to glycolysis to sustain robust proliferation as early as in 1924,[3,4] it is only recently that targeting cancer metabolism has emerged as a therapeutic strategy for the development of antineoplastic agents.[5] Among the metabolic targets, considerable attention has been given to the biosynthetic pathways leading to nicotinamide adenine dinucleotide (NAD).[6,7] NAD is an important cofactor in redox reactions and serves as the substrate for poly (ADP-ribose) polymerases (PARPs),[8] mono (ADP-ribose) transferases (ARTs),[2] and sirtuins,[9] which convert NAD to nicotinamide (NAM). In cancer cells, NAD is rapidly consumed because of increased demand for ATP and high activity of NAD-consuming enzymes such as PARPs and Sirtuins.[9–11] Thus, malignant cells are more sensitive to NAD availability as compared with normal cells. Rapidly proliferating cancers requires constant re-synthesis of NAD in order to maintain sufficient levels for cell survival. Biochemically, there are three main pathways to generate NAD in eukaryotic cells: a de novo pathway using tryptophan (Trp) as the precursor, the primary salvage pathway in which NAD is recycled from NAM, and the alternative salvage pathway using nicotinic acid. The main source of cellular NAD is from the primary salvage pathway using NAM as the precursor.[12] Nicotinamide phosphoribosyltransferase (Nampt) catalyzes the rate-limiting step.[13,14] Given that Nampt plays a key role in the replenishment of NAD, inhibition of Nampt can dramatically impact NAD metabolism and cancer proliferation. Thus, Nampt is considered as an attractive target for the development of new cancer therapies.

To date, several classes of Nampt inhibitors have been reported in the scientific and patent literatures.[2,12,15] The most advanced compounds FK866, CHS828 and its prodrug GMX1777 (Fig. 1) have entered the human clinical trials.[16–18] FK866 is in phase 2 clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL), while CHS828 is in phase 1 trials against metastatic melanoma. However, the clinical development of FK866 has been hampered by dose-limiting thrombocytopenia.[19] CHS828 was also reported with thrombocytopenia and various gastrointestinal symptoms.[20] With regard to limited classes of small-molecule Nampt inhibitors, it is highly desirable to discover new inhibitors with novel chemical scaffolds and potent antiproliferative activity (e.g. compound **1**).[15,21,22]

The pharmacophoric model (Fig. 1) of the Nampt inhibitors consists of a cap group (typically a *meta* or *para* substituted pyridine), a connecting unit, a linker and a tail group.[2] Previously, we described the identification of compound **2** (Fig. 1) as a novel Nampt inhibitor by high throughput screening.[15] It showed submicromolar activity against Nampt ($IC_{50} = 0.15 \,\mu M$). Interestingly, the benzothiophene inhibitor **2** did not contain a pyridine or nitrogen-containing heterocycle moiety in the cap group. This molecule demonstrated that a non-nitrogen heterocycle NAM mimetic can

 * Corresponding authors. Tel.: +86 21 81871271 (C.M.), +86 21 81871239 (C.S.).
 E-mail addresses: cymiao@smmu.edu.cn (C. Miao), shengcq@hotmail.com (C. Sheng).
 [†] These authors contributed equally to this work.

ARTICLE IN PRESS

2   *W. Chen et al. / Bioorg. Med. Chem. Lett. xxx (2016) xxx–xxx*

Figure 1. Pharmacophoric model and chemical structures of the Nampt inhibitors.

be tolerated in the Nampt binding site. However, the in vitro antitumor potency of inhibitor **2** was poor (Table 1) and its structure–activity relationships (SAR) is still unknown. Thus, a series of novel benzothiophene Nampt inhibitors were designed, synthesized and assayed.

The synthetic routes of the target compounds were shown in Schemes 1–3. As depicted in Scheme 1, commercially available compound **3** was reacted with the substituted carboxylic acids in the present of HBTU and Et$_3$N to give target compounds **7**, **8a–c**, and **9**. Compounds **13a–b** were synthesized according to the procedures outlined in Scheme 2. Treatment of compound **3** and (*tert*-butoxycarbonyl)glycine (**10**) via condensation reaction afforded the key intermediate **11**. After the removal of the Boc protecting group of **11**, amide **12** was coupled with carboxylic acids (**5a–b**) to give the target compounds **13a–b**. Finally, the compounds bearing the imidazole tails (**15a–b**, **16a–c**, **17**) were synthesized using the condition similar to that of compound **7** (Scheme 3). Condensation of 3-(1*H*-imidazol-1-yl)propan-1-amine (**14**) with carboxylic acids afforded the target compounds **15a–b**, **16a–c**, and **17**.

Our previously described fluorometric assay was used to evaluate the Nampt inhibitory activity.[15] As shown in Table 1, most of the benzothiophene derivatives exhibited moderate to good anti-Nampt activity. The replacement of the benzothiophene scaffold with benzofuran (compound **7**) led to significant decrease of the Nampt inhibitory activity. The removal of the benzene ring of the benzothiophene scaffold afforded the substituted thiophene derivatives. Introduction of methyl group at the thiophene C-5 position yielded several good Nampt inhibitors. Compounds **8b**, **13b** and **16b** had an IC$_{50}$ value of 0.86 μM, 0.95 μM and 0.17 μM, respectively. Compound **16b** showed comparable Nampt inhibitory activity to lead compound **2** (IC$_{50}$ = 0.15 μM). However, compounds with a nitro group at the C-5 position (**8c** and **16c**) lost their inhibitory potency in both biochemical and cell-based assays. Pyridine is a classical cap group in the known Nampt inhibitors. However, when benzothiophene was replaced by the *meta* substituted pyridine, compounds **9** and **17** were inactive in the anti-Nampt and antiproliferative assay. Thus, the SAR of the benzothiophenes might be different from that of classical Nampt inhibitors.

The synthesized compounds were also evaluated for antiproliferative activities against the HCT116 (colon cancer cells), MDA-MB-231 (breast cancer cells) and HepG2 (liver cancer cells) human cancer cell lines using the standard MTT assay.[23] As shown in

Table 1
Nampt inhibition and in vitro antitumor activity of target compounds

Compd	IC$_{50}$ (μM)			
	Nampt	HCT116	MDA-MB-231	HepG2
7	1.4 ± 0.11	159 ± 11	>371	137 ± 14
8a	5.3 ± 0.32	169 ± 21	191 ± 14	99 ± 8.7
8b	0.86 ± 0.05	>307	>307	>307
8c	>10	86 ± 9.2	>328	80 ± 9.0
9	>10	>401	>401	>401
13a	>10	196 ± 15	>328	47 ± 4.2
13b	0.95 ± 0.08	>401	>401	>401
15a	1.1 ± 0.12	25 ± 1.9	36 ± 2.8	5.2 ± 0.45
15b	1.0 ± 0.09	61 ± 5.7	10 ± 1.2	11 ± 1.3
16a	>10	198 ± 16	>276	102 ± 12
16b	0.17 ± 0.01	>320	>320	3.9 ± 0.33
16c	>10	>390	>390	60 ± 5.5
17	>10	>276	>276	>276
2	0.15 ± 0.02	281 ± 20	>293	82 ± 7.9

Table 1, these compounds showed better activity against HepG2 than the other two cell lines. Moreover, most target compounds exhibited better antiproliferative potency than lead compound **2**. Among them, compound **16b** exhibited the best antiproliferative activity against the HepG2 cell line (IC$_{50}$ = 3.9 μM). Despite good in vitro Nampt inhibitory potency, the 5-methylthiophenes **8b** and **13b** lost activity for cancer cell lines. In consistent with the Nampt inhibitory activities, compounds containing the pyridine in cap group (**9** and **17**) were completely inactive in the antitumor assays.

Molecular docking studies were performed using GOLD 5.0[24] to investigate the binding mode of compounds **2** and **16b** with Nampt. The crystal structure of Nampt in complex with FK866 was obtained from protein database bank (PDB ID: 2GVJ)[25] and prepared for molecular docking analysis in Discovery Studio 3.0[26] by removing the ligand from the binding pocket, merging nonpolar hydrogens, adding polar hydrogens, and rendering Gasteiger charges to each atom. Conformations were generated by genetic algorithm and scored using GoldScore as fitness function. The best conformation was chosen to analyze the ligand–protein interaction. As depicted in Figure 2, the benzothiophene scaffold of compound **2** was sandwiched between the side chains of Phe193 and Tyr18 and formed π–π interactions. The oxygen atom of amide formed a hydrogen bond with the hydroxyl group of Ser275. The phenyl and alkyl group interacted with Val242, Ala244 and

ARTICLE IN PRESS

W. Chen et al./Bioorg. Med. Chem. Lett. xxx (2016) xxx–xxx

3

Scheme 1. Reagents and conditions: (a) HBTU, Et$_3$N, DMF, rt, 2 h, 64–83%.

Scheme 2. Reagents and conditions: (a) HBTU, Et$_3$N, DMF, rt, 2 h, 85%; (b) CF$_3$COOH, DCM, rt, 1 h, 70%; (c) HBTU, DIPEA, DMF, 2 h, 67–71%.

Scheme 3. Reagents and conditions: (a) HBTU, Et$_3$N, DMF, rt, 2 h, 59–78%.

Ile309 mainly through hydrophobic and van der Waals interactions. Compound **16b** had a similar binding mode to lead compound **2**. The thiophene intercalated into Phe193 and Tyr18 and formed face-to-face π–π stacking interaction. Besides the hydrogen bonding interaction between the amide oxygen atom and Ser275, an additional hydrogen bond was observed between the nitrogen atom of imidazole and His191. The alkyl group attached to the imidazole formed hydrophobic and van der Waals interactions with Ala244 and Ile309. The terminal imidazole group was located at the outside of active site and faced to the solvent.

To investigate whether the target compounds can lead to cell death by apoptosis, an annexin VFITC/propidium iodide (PI)

binding assay was performed. HepG2 cells were treated with vehicle alone or compounds **15a** and **16b** at 5 μM for 48 h, stained with Annexin V-FITC and PI, and analyzed by flow cytometry. As shown in Figure 3, both **15a** and **16b** caused significant induction of apoptosis in the Hep2 cell line. The percentage of apoptotic cells for **15a** and **16b** was 26.30% and 48.54% (Q2 + Q4), respectively. The results revealed that compounds **15a** and **16b** could efficiently induce apoptosis of HepG2 cells.

In summary, SARs of the novel benzothiophene Nampt inhibitor was obtained. Several derivatives demonstrated good Nampt inhibitory potency and antiproliferative activity. Especially, compound **16b** was proven to a potent Nampt inhibitor, which also showed

4

W. Chen et al./Bioorg. Med. Chem. Lett. xxx (2016) xxx–xxx

Figure 2. Binding mode of compound **2** (A) and **16b** (B) in the active site of Nampt (PDB ID: 2GVJ). The figure was generated using PyMol (http://www.pymol.org/).


Figure 3. Cell apoptosis induced by compound **15a** and **16b**. HepG2 cells were treated with DMSO and 5 μM of compounds for 48 h. Apoptosis was examined by flow cytometer ($n = 3$).

good antitumor activity and remarkable apoptotic effect against the HepG2 cell line. Taken together, the present study provides a good starting point for the development of novel Nampt inhibitors. Further structural optimization is in progress.

Acknowledgements

Supplementary data

Supplementary data (experimental protocols and structural characterization of target compounds) associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmcl.2015.12.101.

References and notes

1. Yuneva, M. O.; Fan, T. W.; Allen, T. D.; Higashi, R. M.; Ferraris, D. V.; Tsukamoto, T.; Mates, J. M.; Alonso, F. J.; Wang, C.; Seo, Y.; Chen, X.; Bishop, J. M. *Cell Metab.* **2012**, *15*, 157.
2. Galli, U.; Travelli, C.; Massarotti, A.; Fakhfouri, G.; Rahimian, R.; Tron, G. C.; Genazzani, A. A. *J. Med. Chem.* **2013**, *56*, 6279.
3. Koppenol, W. H.; Bounds, P. L.; Dang, C. V. *Nat. Rev. Cancer* **2011**, *11*, 325.
4. Vander Heiden, M. G. *Nat. Rev. Drug Disc.* **2011**, *10*, 671.
5. Galluzzi, L.; Kepp, O.; Vander Heiden, M. G.; Kroemer, G. *Nat. Rev. Drug Disc.* **2013**, *12*, 829.
6. Garten, A.; Petzold, S.; Korner, A.; Imai, S.; Kiess, W. *Trends Endocrinol. Metab.* **2009**, *20*, 130.
7. Galli, M.; Van Gool, F.; Rongvaux, A.; Andris, F.; Leo, O. *Cancer Res.* **2010**, *70*, 8.
8. Diefenbach, J.; Burkle, A. *Cell. Mol. Life Sci.* **2005**, *62*, 721.
9. Saunders, L. R.; Verdin, E. *Oncogene* **2007**, *26*, 5489.
10. Hageman, G. J.; Stierum, R. H. *Mutat. Res.* **2001**, *475*, 45.
11. Nomura, F.; Yaguchi, M.; Togawa, A.; Miyazaki, M.; Isobe, K.; Miyake, M.; Noda, M.; Nakai, T. *J. Gastroenterol. Hepatol.* **2000**, *15*, 529.
12. Sampath, D.; Zabka, T. S.; Misner, D. L.; O'Brien, T.; Dragovich, P. S. *Pharmacol. Ther.* **2015**, *151*, 16.
13. Foster, J. W.; Moat, A. G. *Microbiol. Rev.* **1980**, *44*, 83.
14. Magni, G.; Amici, A.; Emanuelli, M.; Orsomando, G.; Raffaelli, N.; Ruggieri, S. *Cell. Mol. Life Sci.* **2004**, *61*, 19.
15. Xu, T. Y.; Zhang, S. L.; Dong, G. Q.; Liu, X. Z.; Wang, X.; Lv, X. Q.; Qian, Q. J.; Zhang, R. Y.; Sheng, S. Q.; Miao, C. Y. *Sci. Rep.* **2015**, *5*, 10043.
16. Hasmann, M.; Schemainda, I. *Cancer Res.* **2003**, *63*, 7436.
17. Watson, M.; Roulston, A.; Belec, L.; Billot, X.; Marcellus, R.; Bedard, D.; Bernier, C.; Branchaud, S.; Chan, H.; Dairi, K.; Gilbert, K.; Goulet, D.; Gratton, M. O.; Isakau, H.; Jang, A.; Khadir, A.; Koch, E.; Lavoie, M.; Lawless, M.; Nguyen, M.; Paquette, D.; Turcotte, E.; Berger, A.; Mitchell, M.; Shore, G. C.; Beauparlant, P. *Mol. Cell. Biol.* **2009**, *29*, 5872.
18. Beauparlant, P.; Bedard, D.; Bernier, C.; Chan, H.; Gilbert, K.; Goulet, D.; Gratton, M. O.; Lavoie, M.; Roulston, A.; Turcotte, E.; Watson, M. *Anticancer Drugs* **2009**, *20*, 346.
19. Holen, K.; Saltz, L. B.; Hollywood, E.; Burk, K.; Hanauske, A. R. *Invest. New Drugs* **2008**, *26*, 45.
20. von Heideman, A.; Berglund, A.; Larsson, R.; Nygren, P. *Cancer Chemother. Pharmacol.* **2010**, *65*, 1165.
21. Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Han, B.; Ho, Y. C.; Kley, N.; Lin, J.; Reynolds, D. J.; Sharma, G.; Smith, C. C.; Wang, Z.; Dragovich, P. S.; Gunzner-Toste, J.; Liederer, B. M.; Ly, J.; O'Brien, T.; Oh, A.; Wang, L.; Wang, W.; Xiao, Y.; Zak, M.; Zhao, G.; Yuen, P. W.; Bair, K. W. *J. Med. Chem.* **2013**, *56*, 6413.
22. Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Han, B.; Ho, Y. C.; Kley, N.; Lin, J.; Reynolds, D. J.; Sharma, G.; Smith, C. C.; Wang, Z.; Dragovich, P. S.; Oh, A.; Wang, W.; Zak, M.; Gunzner-Toste, J.; Zhao, G.; Yuen, P. W.; Bair, K. W. *J. Med. Chem.* **2013**, *56*, 4921.
23. Dong, G.; Sheng, C.; Wang, S.; Miao, Z.; Yao, J.; Zhang, W. *J. Med. Chem.* **2010**, *53*, 7521.
24. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. *J. Mol. Biol.* **1997**, *267*, 727.
25. Khan, J. A.; Tao, X.; Tong, L. *Nat. Struct. Mol. Biol.* **2006**, *13*, 582.
26. Accelrys Software Inc., San Diego; http://www.accelrys.com.